

Application No. 10/580,108  
Response to Office Action of 11/12/2008  
Page 2 of 18

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

**Listing of The Claims:**

Claim 1. (Currently Amended) A targeted glycoconjugate comprising a bioactive agent and a targeting compound, wherein the bioactive agent and targeting compound are joined by a modified saccharide compound, and wherein the modified saccharide compound comprises galactose and a reactive functional group attached to the C2 position of the galactose ring.

Claim 2. (Original) The glycoconjugate of claim 1 wherein the bioactive agent comprises a polypeptide; releasing factor; releasing factor inhibitor; carbohydrate; nucleic acid; vaccine; anti-antibiotic; antiviral agent; anti-fungal agent; analgesics anesthetic; anti-helminthic; anti-arthritis agent; anti-asthmatic agent; anticonvulsant; antidepressant; anti-diabetic agent; anti-diarrheal; anticonvulsant; antihistamine; anti-inflammatory agent; toxin, anti-migraine preparation; anti-nauseant; anticancer agent; anti-parkinsonism drug; ; anti-psychotic; antipyretic; anti-spasmodic; anti-cholinergic; sympathomimetic; xanthine derivative; cardiovascular agent; anti-arrhythmic; anti-hyperlipidemic agent; anti-hypertensive; diuretic; anti-diuretic; receptor agonist; receptor antagonist; vasodilator; central nervous system stimulant; vasoconstrictor; cough and cold preparation; enzyme inhibitor; hormone; hypnotic; agent; muscle relaxant; parasympatholytic; central nervous system stimulant; diuretic; hypnoticsleukotriene inhibitor; mitotic inhibitor; muscle relaxant; genetic material; psychostimulant; sedative; anabolic agent; vitamin; herbal remedy; anti-metabolic agent; anxiolytic; attention deficit disorder (ADD) drug; attention deficit hyperactivity disorder (ADHD) drug; neuroleptic agent; or tranquilizer.

Claim 3. (Original) The glycoconjugate of claim 1, wherein the targeting compound comprises a glycoprotein, glycolipid or carbohydrate.

BOS2 718632.1

Application No. 10/580,108  
Response to Office Action of 11/12/2008  
Page 3 of 18

Claim 4. (Withdrawn) The glycoconjugate of claim 1, wherein the targeting compound comprises GlcNAc.

Claim 5. (Withdrawn) The glycoconjugate of claim 1, wherein the targeting compound is a receptor ligand or an antibody.

Claim 6. (Withdrawn) The glycoconjugate of claim 5, wherein the antibody is a polyclonal antibody.

Claim 7. (Withdrawn) The glycoconjugate of claim 5, wherein the antibody is a monoclonal antibody.

Claim 8. (Withdrawn) The glycoconjugate of claim 1, wherein the modified saccharide compound comprises galactose, glucose, D-deoxy-glc, arabinose, GalNAc or GlcNAc.

Claim 9. (Currently Amended) The glycoconjugate of ~~claim 8~~claim 1, wherein the modified saccharide compound further comprises a reactive functional group.

Claim 10. (Original) The glycoconjugate of claim 9, wherein the reactive functional group comprises an amino, hydroxy, carboxyl, thiol, phosphate, phosphinate, ketone, sulfate or sulfinate group.

Claim 11 – 42 (Cancelled)

Claim 43. (Original) A pharmaceutical composition comprising the glycoconjugate of claim 1 and a pharmaceutically acceptable carrier.

BOS2 718632.1

Application No. 10/580,108  
Response to Office Action of 11/12/2008  
Page 4 of 18

Claim 44. (Previously Presented) A kit comprising the glycoconjugate of claim 1 and instructions for use in a therapeutic or diagnostic method.

Claim 45. (Original) A glycoconjugate according to claim 1 for use in medical therapy.

Claims 46 - 48. (Cancelled)

Claim 49. (New) A targeted glycoconjugate comprising a bioactive agent and a targeting compound, wherein the bioactive agent and targeting compound are joined by a modified saccharide compound, and wherein the modified saccharide compound comprises galactose and a reactive functional group attached to the C2 position of the galactose ring, wherein the reactive functional group is a ketone group.

BOS2 718632.1